{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:27:37Z","timestamp":1789133257537,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Rapidly progressive interstitial lung disease presents as a severe complication of juvenile dermatomyositis, particularly when associated with anti-melanoma differentiation-associated gene 5. We report a pediatric case that underscores the necessity for clinicians to maintain a high index of suspicion for early identification and management. <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A previously healthy 7-year-old White girl presented with a 6-week history of generalized weakness, fever, joint pain, and abdominal pain. Initial examination revealed hypoxia, tachypnea, and hepatosplenomegaly. Laboratory tests were marked by thrombocytopenia, lymphopenia, elevated liver enzymes, high ferritin, high triglyceride, elevated muscle enzymes, and increased soluble IL-2 receptor, suggesting macrophage activation syndrome that was and managed with dexamethasone 5\u00a0mg\/kg\/m<jats:sup>2<\/jats:sup> twice daily. There were no pathogenic skin features of juvenile dermatomyositis, except for nailfold capillary dropout. Initial cell counts revealed that her white blood cell count was 2.87\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L, hemoglobin was 105\u00a0g\/L, platelet was 90\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L, and ferritin was 2000.6\u00a0\u03bcg\/L and antinuclear and anti-Ro52 antibodies were positive. She was noted to have peripheral muscle weakness. Her clinical course was marked by progressive respiratory failure requiring mechanical ventilation with imaging revealing diffuse alveolar ground-glass opacities. The infectious work up was negative for bacterial, fungal, and viral ethologies including\u00a0Epstein\u2013Barr virus; hepatitis A virus, hepatitis B, hepatitis C, and hepatitis E viruses; parvovirus B19; cytomegalovirus; herpes simplex virus 1 and 2; and human herpesvirus 6. With the interstitial lung disease picture, pulse doses of intravenous methylprednisolone and intravenous immunoglobulin were initiated. She developed a significant air leak that was managed with bilateral chest tubes. Her significant hypoxemia required cannulation to veno-venous extracorporeal membrane oxygenation. The diagnosis of anti-melanoma differentiation-associated gene 5 antibody-associated juvenile dermatomyositis was confirmed by antibody testing. Additional immunomodulatory therapy was utilized during the treatment course with no noted improvement. She was not a candidate for lung transplantation, and in the face of additional organ dysfunction, life-sustaining therapies were withdrawn on day 32 of intensive care unit admission. <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This case demonstrates the diagnostic and therapeutic challenges in patients with rapidly progressive interstitial lung disease in the context of anti-melanoma differentiation-associated gene 5 associated juvenile dermatomyositis, who may not present with overt muscle and cutaneous features of juvenile dermatomyositis and whose lung disease can progress very rapidly. A high index of suspicion among clinicians is critical, and expedited diagnostic serology may assist with earlier diagnosis and initiation of therapy. Extracorporeal membrane oxygenation can be utilized as a bridge to diagnosis in the setting of severe refractory hypoxemic respiratory failure. However, despite aggressive treatment, the prognosis remains challenging.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13256-025-05336-6","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T09:02:51Z","timestamp":1749805371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-melanoma differentiation-associated gene 5 antibody associated rapidly progressive interstitial lung disease in a pediatric patient: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Thitima","family":"Sirimontakan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Kritzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta","family":"Limenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Mastrangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briseida","family":"Mema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7562-549X","authenticated-orcid":false,"given":"Haifa","family":"Mtaweh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"6","key":"5336_CR1","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00296-021-04819-1","volume":"41","author":"P Mehta","year":"2021","unstructured":"Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int. 2021;41(6):1021\u201336.","journal-title":"Rheumatol Int"},{"issue":"5","key":"5336_CR2","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/rheumatology\/keu385","volume":"54","author":"N Kobayashi","year":"2015","unstructured":"Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology. 2015;54(5):784\u201391.","journal-title":"Rheumatology"},{"issue":"3","key":"5336_CR3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-063268","volume":"153","author":"K Ciaglia","year":"2024","unstructured":"Ciaglia K, Ghawji M, Caraballo M, Sloan E. Successful treatment of rapidly progressive interstitial lung disease in juvenile dermatomyositis. Pediatrics. 2024;153(3): e2023063268.","journal-title":"Pediatrics"},{"issue":"1","key":"5336_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12969-021-00595-1","volume":"19","author":"TW Yeung","year":"2021","unstructured":"Yeung TW, Cheong KN, Lau YL, Tse KN. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review. Pediatr Rheumatol Online J. 2021;19(1):103.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"5336_CR5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jpeds.2010.11.033","volume":"158","author":"I Kobayashi","year":"2011","unstructured":"Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr. 2011;158(4):675\u20137.","journal-title":"J Pediatr"},{"issue":"8S","key":"5336_CR6","doi-asserted-by":"publisher","first-page":"S798","DOI":"10.1097\/RHU.0000000000001460","volume":"27","author":"M Shimizu","year":"2021","unstructured":"Shimizu M, Inoue N, Takeda Y, Kidouchi K, Fujita N, Fujiki T, et al. Concurrent treatment with rituximab and plasma exchange for rapidly progressive interstitial lung disease complicating anti-MDA5 antibody-positive juvenile dermatomyositis. J Clin Rheumatol. 2021;27(8S):S798\u20139.","journal-title":"J Clin Rheumatol"},{"issue":"167","key":"5336_CR7","doi-asserted-by":"publisher","first-page":"220188","DOI":"10.1183\/16000617.0188-2022","volume":"32","author":"N Nathan","year":"2023","unstructured":"Nathan N, Griese M, Michel K, Carlens J, Gilbert C, Emiralioglu N, et al. Diagnostic workup of childhood interstitial lung disease. Eur Respir Rev. 2023;32(167):220188.","journal-title":"Eur Respir Rev"},{"issue":"2","key":"5336_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/25785826.2024.2336687","volume":"47","author":"S Yamazaki","year":"2024","unstructured":"Yamazaki S, Shimizu M, Yakabe A, Inage E, Jimbo K, Suzuki M, et al. Successful treatment with tofacitinib for anti-melanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature. Immunol Med. 2024;47(2):110\u20137.","journal-title":"Immunol Med"},{"issue":"2","key":"5336_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/1756-185X.14258","volume":"25","author":"PLP Chan Ng","year":"2022","unstructured":"Chan Ng PLP, Mopur A, Goh DYT, Ramamurthy MB, Lim MTC, Lim LK, et al. Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease. Int J Rheum Dis. 2022;25(2):228\u201331.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"5336_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/24725625.2020.1832755","volume":"5","author":"C Quintana-Ortega","year":"2021","unstructured":"Quintana-Ortega C, Remesal A, de Valbuena MR, de la Serna O, Laplaza-Gonz\u00e1lez M, \u00c1lvarez-Rojas E, et al. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report. Modern Rheumatol Case Rep. 2021;5(1):101\u20137.","journal-title":"Modern Rheumatol Case Rep"},{"issue":"1","key":"5336_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12969-022-00723-5","volume":"20","author":"K Nishi","year":"2022","unstructured":"Nishi K, Ogura M, Tamai N, Gima M, Ide K, Koinuma G, et al. Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review. Pediatr Rheumatol Online J. 2022;20(1):60.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"5336_CR12","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1080\/14397595.2018.1511025","volume":"29","author":"N Iwata","year":"2019","unstructured":"Iwata N, Nakaseko H, Kohagura T, Yasuoka R, Abe N, Kawabe S, et al. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: experience at a single center in Japan. Mod Rheumatol. 2019;29(5):802\u20137.","journal-title":"Mod Rheumatol"},{"issue":"8","key":"5336_CR13","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1093\/rheumatology\/kez525","volume":"59","author":"I Melki","year":"2020","unstructured":"Melki I, Devilliers H, Gitiaux C, Bondet V, Duffy D, Charuel J-L, et al. Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-\u03b1 signalling. Rheumatology. 2020;59(8):1927\u201337.","journal-title":"Rheumatology"},{"issue":"4","key":"5336_CR14","doi-asserted-by":"publisher","first-page":"R138","DOI":"10.1186\/ar4600","volume":"16","author":"SL Tansley","year":"2014","unstructured":"Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther. 2014;16(4):R138.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"5336_CR15","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/rheumatology\/keaa429","volume":"60","author":"G Mamyrova","year":"2021","unstructured":"Mamyrova G, Kishi T, Shi M, Targoff IN, Huber AM, Curiel RV, et al. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. Rheumatology. 2021;60(4):1839\u201349.","journal-title":"Rheumatology"},{"issue":"3","key":"5336_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3899\/jrheum.160682","volume":"44","author":"S Moghadam-Kia","year":"2017","unstructured":"Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J Rheumatol. 2017;44(3):319\u201325.","journal-title":"J Rheumatol"},{"key":"5336_CR17","doi-asserted-by":"publisher","first-page":"204062232210981","DOI":"10.1177\/20406223221098128","volume":"13","author":"Y Ding","year":"2022","unstructured":"Ding Y, Ge Y. Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis complicated with macrophage activation syndrome. Ther Adv Chronic Dis. 2022;13:20406223221098130.","journal-title":"Ther Adv Chronic Dis"},{"issue":"4","key":"5336_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40674-021-00186-x","volume":"7","author":"A Selva-O\u2019Callaghan","year":"2021","unstructured":"Selva-O\u2019Callaghan A, Romero-Bueno F, Trallero-Aragu\u00e1s E, Gil-Vila A, Ruiz-Rodr\u00edguez JC, S\u00e1nchez-Pernaute O, et al. Pharmacologic treatment of anti-MDA5 rapidly progressive interstitial lung disease. Curr Treatm Opt Rheumatol. 2021;7(4):319\u201333.","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"5336_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12016-020-08822-5","volume":"60","author":"W Wu","year":"2021","unstructured":"Wu W, Guo L, Fu Y, Wang K, Zhang D, Xu W, et al. Interstitial lung disease in anti-MDA5 positive dermatomyositis. Clin Rev Allergy Immunol. 2021;60:293\u2013304.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"5336_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/rheumatology\/kez357","volume":"59","author":"Y Abe","year":"2020","unstructured":"Abe Y, Kusaoi M, Tada K, Yamaji K, Tamura N. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology. 2020;59(4):767\u201371.","journal-title":"Rheumatology"},{"key":"5336_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.epsc.2016.04.009","volume":"9","author":"R Mejias","year":"2016","unstructured":"Mejias R, Schad C, Okochi S, Cheung EW, Starr AJ, Kadenhe-Chiweshe A, et al. Bridge to diagnosis: the use of extracorporeal membrane oxygenation in a child with interstitial lung disease secondary to clinically amyopathic dermatomyositis. J Pediatr Surg Case Rep. 2016;9:31\u20133.","journal-title":"J Pediatr Surg Case Rep"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05336-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05336-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05336-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T09:02:52Z","timestamp":1749805372000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05336-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5336"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05336-6","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As per institutional research ethics board, the legal guardians have provided informed consent for the preparation and publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"274"}}